#$%^&*AU2017203395A120170608.pdf#####1: dar Interwoven NRPortbl DCC DAR 14551428_i.docx-19 05/2017 Abstract The invention is directed, in part, to selective cancer treatment regimes based on assaying for the presence or absence of a mutation in a nucleic acid that encodes MLL1 or for the presence of reduced levels of MLL1.